1244 3D Medicines, Inc. HKEX · China

3D Medicines (1244) news

3D Medicines, Inc. is a public biotech or pharmaceutical company listed on HKEX under the ticker 1244, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest 3D Medicines news

We have not published a story on 3D Medicines yet. When there is news, it will appear here.

Questions about 3D Medicines

What is the ticker symbol of 3D Medicines?

3D Medicines, Inc. trades under the ticker 1244 on HKEX.

Where is 3D Medicines listed?

3D Medicines, Inc. is listed on HKEX.

Which country or territory is 3D Medicines listed under?

Our directory records 3D Medicines, Inc. under China.

What does 3D Medicines do?

Our directory classifies 3D Medicines, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of 3D Medicines?

The ISIN recorded for 3D Medicines, Inc. is KYG8872R1011.

Does aibio.space cover 3D Medicines?

aibio.space lists 3D Medicines, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to 3D Medicines?

Companies in our directory listed in the same country and business area as 3D Medicines: Zhejiang Huahai Pharmaceutical Co., BrightGene Bio-Medical Technology Co., Jiangsu Bioperfectus Technologies Co., Tianjin Lisheng Pharmaceutical Co., Jinyu Bio-Technology Co., Suzhou Zelgen Biopharmaceuticals Co..

Investor discussion: 3D Medicines

Members talk about 3D Medicines (1244). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at 3D Medicines, newest first. Each line links the filing it comes from.

Sep 17, 2026Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION. Source
Jul 27, 2026Legal
Legal proceedings: INSIDE INFORMATION ANNOUNCEMENT ON THE ARBITRATION PROCEEDINGS AGAINST SELLAS LIFE SCIENCES GROUP, INC.. Source
Jun 5, 2026Financings
Share or debt issue: GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; RE-ELECTION OF RETIRING DIRECTORS; RE-APPOINTMENT OF AUDITOR; AND NOTICE OF ANNUAL GENERAL MEETING. Source
Apr 1, 2026Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION; AND CLARIFICATION ANNOUNCEMENT ON THE ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025. Source
Jul 14, 2025Mergers
Transaction under the Listing Rules: SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE STRATEGIC COOPERATION AGREEMENT AND UPDATES ON CIVIL PROCEEDINGS. Source
Jul 2, 2025Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION CONNECTED TRANSACTION AT SUBSIDIARY LEVEL IN RESPECT OF THE STRATEGIC COOPERATION AGREEMENT. Source
Jun 5, 2025Financings
Share or debt issue: GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; RE-ELECTION OF RETIRING DIRECTORS; PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR; RE-APPOINTMENT OF AUDITOR; AND NOTICE OF ANNUAL GENERAL MEETING. Source

Press releases

Headlines of 3D Medicines's own announcements, newest first. Each opens the full release on the newswire that carried it.

Oct 2, 2026HKEXnews
CHANGE OF PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE
Sep 17, 2026HKEXnews
DISCLOSEABLE TRANSACTION
Aug 31, 2026HKEXnews
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026
Aug 18, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT UPDATE ON COMPLETION OF ENFORCEMENT OF THE ARBITRAL AWARD WITH SELLAS LIFE SCIENCES GROUP, INC.
Aug 7, 2026HKEXnews
RESIGNATION OF NON-EXECUTIVE DIRECTOR AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR
Aug 4, 2026HKEXnews
CHANGE OF PROCESS AGENT AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG
Jul 27, 2026HKEXnews
INSIDE INFORMATION ANNOUNCEMENT ON THE ARBITRATION PROCEEDINGS AGAINST SELLAS LIFE SCIENCES GROUP, INC.
Jun 30, 2026HKEXnews
UPDATE ON THE QUALIFICATION OF COMPANY SECRETARY; RESIGNATION OF JOINT COMPANY SECRETARY AND CHANGE OF AUTHORISED REPRESENTATIVE
Jun 30, 2026HKEXnews
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 30, 2026
Jun 5, 2026HKEXnews
NOTICE OF ANNUAL GENERAL MEETING
Jun 5, 2026HKEXnews
GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; RE-ELECTION OF RETIRING DIRECTORS; RE-APPOINTMENT OF AUDITOR; AND NOTICE OF ANNUAL GENERAL MEETING
May 27, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT PHASE III STUDY RESULTS OF ENVAFOLIMAB PLUS GEMOX IN FIRST-LINE TREATMENT OF ADVANCED BILIARY TRACT CANCER TO BE OFFICIALLY PRESENTED AT 2026 ASCO ANNUAL MEETING
May 21, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT EARLY COMPLETION OF ENROLLMENT IN THE PHASE III CLINICAL TRIAL OF ENVAFOLIMAB FOR NEOADJUVANT/ADJUVANT TREATMENT OF NON-SMALL CELL LUNG CANCER
Apr 1, 2026HKEXnews
DISCLOSEABLE TRANSACTION; AND CLARIFICATION ANNOUNCEMENT ON THE ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Mar 31, 2026HKEXnews
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Feb 9, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT ENVAFOLIMAB SUPPLEMENTAL APPLICATION FOR CONDITIONAL-TO-REGULAR APPROVAL TRANSITION ACCEPTED BY NMPA
Jan 12, 2026HKEXnews
CHANGE OF CHIEF FINANCIAL OFFICER
Jan 9, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION FOR FIRST-LINE TREATMENT OF BILIARY TRACT CANCER OF ENVAFOLIMAB ACCEPTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Dec 22, 2025HKEXnews
VOLUNTARY ANNOUNCEMENT ENVAFOLIMAB GRANTED ORPHAN-DRUG DESIGNATION FOR TREATMENT OF GASTRIC CANCER AND GASTRO-ESOPHAGEAL JUNCTION CANCER INDICATIONS
Aug 29, 2025HKEXnews
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:1244 on TradingView.

Listing details

Company: 3D Medicines, Inc.
Ticker: 1244
Listing: HKEX
Country or territory: China
Business scope: Pharmaceuticals: Major
ISIN: KYG8872R1011
Last quote in directory: 2026-10-22
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction